CommercialPrior AuthHigh impact
State and School Employees' Health Insurance Plan - Interleukin-5 Antagonist Monoclonal Antibodies
Blue Cross & Blue Shield of Mississippi·Pulmonology, Allergy & Immunology, ENT (Ear, Nose & Throat) +1 more·Medical Policy
We identified it
Jun 20, 2026
Summary
State and School Employees' Health Insurance Plan has established new medical policy criteria for interleukin-5 antagonist monoclonal antibodies (Cinqair, Fasenra, Nucala) used to treat severe eosinophilic asthma, EGPA, hypereosinophilic syndrome, and chronic rhinosinusitis with nasal polyps. The policy establishes detailed prior authorization requirements including specific age restrictions, diagnostic criteria, blood eosinophil count thresholds, and mandatory trial of conventional therapies before approval.
Action Required
Immediately: Billing team must implement prior authorization requirements for all interleukin-5 antagonist monoclonal antibody claims (Cinqair, Fasenra, Nucala). Providers must document age-specific criteria, confirmed diagnosis with required lab values (eosinophil counts, FeNO, FEV1), evidence of treatment failures with conventional therapies, and specialist consultation. Update encounter forms and EMR templates to capture required documentation elements. Claims without proper authorization and documentation will be denied.